ストックスクリーナーアプリを入手
32.06
2.13%
0.67
前日終値:
$31.39
開ける：
$31.56
24時間の取引高:
382.23K
Relative Volume:
1.07
時価総額：
$592.47M
収益：
$294.28M
当期純損益:
$367.02M
株価収益率:
1.6953
EPS:
18.9115
ネットキャッシュフロー:
$75.66M
1週間 パフォーマンス:
+7.84%
1か月 パフォーマンス:
+23.55%
6か月 パフォーマンス:
+14.05%
1年 パフォーマンス:
+88.15%
1日の値動き範囲:
$31.56
$32.24
1週間の範囲:
$28.78
$32.24
52週間の値動き範囲:
$16.05
$52.24
Rigel Pharmaceuticals Stock (RIGL) Company Profile
名前
Rigel Pharmaceuticals
セクター
電話
650-624-1100
住所
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
32.06 | 580.09M | 294.28M | 367.02M | 75.66M | 18.91 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-05 | アップグレード | Jefferies | Hold → Buy |
| 2023-04-03 | 再開されました | Piper Sandler | Neutral |
| 2022-06-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-06-08 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | 開始されました | B. Riley Securities | Neutral |
| 2020-11-09 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-11-15 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-09-26 | 再開されました | JP Morgan | Overweight |
| 2019-03-01 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-08-27 | 開始されました | Citigroup | Buy |
| 2018-05-02 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2017-12-21 | 再開されました | Piper Jaffray | Overweight |
| 2017-12-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-11-06 | 再開されました | H.C. Wainwright | Buy |
| 2017-03-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-08-31 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-08-30 | 繰り返されました | Piper Jaffray | Overweight |
| 2016-07-13 | 開始されました | H.C. Wainwright | Buy |
| 2016-06-13 | 開始されました | Piper Jaffray | Overweight |
| 2016-04-22 | アップグレード | JP Morgan | Neutral → Overweight |
| 2013-04-08 | 繰り返されました | Stifel | Buy |
| 2012-11-29 | 開始されました | UBS | Neutral |
| 2012-11-06 | 繰り返されました | Oppenheimer | Outperform |
| 2012-03-26 | 開始されました | Canaccord Genuity | Hold |
| 2010-12-10 | ダウングレード | MP Advisors | Outperform → Market Perform |
すべてを表示
Rigel Pharmaceuticals (RIGL) 最新ニュース
(RIGL) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
RIGL Stock Price, Quote & Chart | RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) - ChartMill
Why Rigel Pharmaceuticals Lost Big in December - AOL.com
Ritholtz Wealth Management Boosts Rigel Pharmaceuticals Holdings - National Today
Ritholtz Wealth Management Acquires 72,999 Shares of Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Why VAALCO Energy, Rigel Pharmaceuticals, and Companhia Siderurgica Nacional Are Today's 3 Best Stoc - Yahoo
Rigel's 2026 Earnings Goal Sets Up Discounted Stock for Potential Clash With Analysts' 82% Price Projections - Bitget
Rigel Pharmaceuticals Was Easy To DismissNow It's Hard To Ignore (Rating Upgrade) - Seeking Alpha
Rigel pharmaceuticals targets $200M-$210M revenue in 2025 with strong Q1 performance - MSN
Rigel Attracts Big Money as Charts Signal Caution - Bitget
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - StreetInsider
Rigel Pharmaceuticals, Inc. (RIGL) stock price, news, quote and history - Yahoo Finance Singapore
Aug Levels: What is the Moat Score of Rigel Pharmaceuticals IncWeekly Market Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn
Rigel Pharmaceuticals Grants Inducement RSUs to New Hires - National Today
Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
Rigel Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Rigel Pharmaceuticals Inc (FRA:RI2) Stock Price & 30 Year Financial Data - GuruFocus
RIGL PE Ratio & Valuation, Is RIGL Overvalued - Intellectia AI
Rigel Pharmaceuticals (RIGL) seeks approval for equity plan share increases at 2026 meeting - Stock Titan
How (RIGL) Movements Inform Risk Allocation Models - Stock Traders Daily
Rigel Pharmaceuticals Balances Breakout Growth With Caution - The Globe and Mail
Why Rigel Pharmaceuticals Shares Tanked - Yahoo
Hennion & Walsh Asset Management Inc. Makes New Investment in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Jim Cramer blesses Rigel Pharmaceuticals as a spec as “it’s doing better than people realize” - MSN
Rigel Pharmaceuticals, Inc. (RIGL) Stock Price, News, Quote & History - Yahoo! Finance Canada
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57 - 富途牛牛
Rigel Pharmaceuticals’ pralsetinib shows efficacy in NSCLC clinical trial - TipRanks
Rigel Pharmaceuticals (RIGL) Reports Promising Results from ARRO - GuruFocus
Rigel announces publication of final ARROW clinical trial data on Gavreto® (pralsetinib) - marketscreener.com
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology - PR Newswire
Rigel Pharmaceuticals Receives 'Moderate Buy' Rating from Analysts - National Today
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Market Review: What is the Moat Score of Rigel Pharmaceuticals Inc2026 Highlights & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Jim Cramer Blesses Rigel Pharmaceuticals as a Spec as “It’s Doing Better Than People Realize” - Insider Monkey
Vanguard realignment leads to 0 shares reported for Rigel (RIGL) - Stock Titan
Jim Cramer Broke Down 16 Stocks Including Pharma Plays for Rising Oil - Insider Monkey
Rigel Pharmaceuticals (RIGL) Q4 earnings miss estimates - MSN
Rigel Pharmaceuticals Q4 2025 earnings preview - MSN
Rigel’s New Olutasidenib Interaction Study Signals Long-Game Strategy for RIGL Investors - TipRanks
Genentech shreds RIPK1 inhibitor from pipeline after early ph. 2 failure - Fierce Biotech
Rigel Pharmaceuticals shows rising relative strength; still shy of key benchmark - MSN
Rigel Pharmaceuticals (RIGL) Just Flashed Golden Cross Signal: Do You Buy? - MSN
Rigel enrols first subject in R289 Phase Ib expansion for MDS - MSN
Rigel Pharmaceuticals (RIGL) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):